+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumonia Therapeutics Market by Therapy Type, Route of Administration, Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast to 2030- Product Image
Pneumonia Therapeutics Market by Therapy Type, Route of Administration, Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast to 2030- Product Image
Sale

Pneumonia Therapeutics Market by Therapy Type, Route of Administration, Distribution Channel, Patient Age Group, Pathogen Type, Indication Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888889
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pneumonia therapeutics market is undergoing rapid transformation as healthcare providers and industry leaders seek new strategies to address evolving pathogen profiles, shifting patient demographics, and increasing regulatory demands.

Market Snapshot: Pneumonia Therapeutics Market

The Pneumonia Therapeutics Market grew from USD 16.64 billion in 2024 to USD 18.19 billion in 2025. With a projected CAGR of 9.02%, the market is anticipated to reach USD 27.96 billion by 2030, highlighting robust expansion and innovation opportunities for industry stakeholders.

Scope & Segmentation

This comprehensive analysis delivers nuanced segmentation and actionable insights across all major segments and regional markets:

  • Therapy Types: Anti-infectives including aminoglycosides, beta lactams, macrolides, quinolones, tetracyclines, antivirals, antifungals; Biologics like immune modulators and monoclonal antibodies; Adjunctive therapies such as corticosteroids and nebulizers; Supportive therapies including fluid management, mechanical ventilation, and oxygen therapy.
  • Routes of Administration: Inhalation, intravenous, and oral formulations to address both inpatient and outpatient care settings.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy reflecting varied patient access requirements.
  • Patient Age Groups: Adult, geriatric, and pediatric cohorts, with differentiated therapy and safety needs.
  • Pathogen Types: Coverage of bacterial, viral, fungal, and atypical infections (including Chlamydophila, Legionella, Mycoplasma) for comprehensive diagnostic and treatment perspectives.
  • Indication Types: Community acquired, hospital acquired, and ventilator associated pneumonia, supporting precise R&D alignment and regulatory strategy.
  • Regional Markets: Americas (with insight into the U.S., Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets like Germany, France, U.K., UAE, South Africa), and Asia-Pacific (focusing on China, India, Japan, Australia, South Korea, and others).
  • Key Players: Strategic profiles of Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, Novartis AG, AstraZeneca plc, Bayer AG, Teva Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories Ltd.

Key Takeaways for Senior Decision-Makers

  • Market growth is shaped by technological advancements such as molecular diagnostics and remote monitoring, improving early detection and enabling more precise, targeted therapy.
  • The adoption of biologic and immune-modulating interventions is expanding, which is redefining clinical approaches and challenging traditional anti-infective dominance in pneumonia care.
  • Shifts in regulatory frameworks and reimbursement models, including greater emphasis on value-based care, are influencing adoption rates and commercial access to new therapies.
  • Segmentation by patient age, pathogen type, and indication supports tailored portfolio strategies and fosters deeper alignment with clinical and market demands across primary and specialty care sectors.
  • Strategic partnerships between technology developers, pharmaceutical manufacturers, and healthcare providers are accelerating the advancement of innovative treatments and supporting next-generation delivery solutions.

Tariff Impact and Supply Chain Resilience

Tariff increases in the United States beginning in 2025 have prompted manufacturers to reassess sourcing and production strategies, favoring regionalization and renegotiated vendor contracts. These adjustments impact cost structures and can influence payer negotiations and market access. Pharmaceutical companies are navigating increased raw material expenses by optimizing procurement and inventory planning. Distributors and parallel markets are emerging as alternative channels, introducing compliance considerations for regulatory teams. Some companies are leveraging localization incentives to enhance supply chain resilience and protect competitiveness in the U.S. market.

Methodology & Data Sources

This report relies on a multi-layered research framework that combines secondary research of peer-reviewed literature, regulatory filings, patents, and market reports with primary interviews among industry experts, healthcare professionals, payers, and executives. Data is cross-validated using market triangulation, public financials, and proprietary surveys, with internal and expert reviews to ensure accuracy.

Pneumonia Therapeutics Market: Why This Report Matters

  • Delivers actionable intelligence on emerging therapies, technology adoption, and evolving regulatory pathways to inform R&D and go-to-market strategies.
  • Guides investment planning and market expansion by mapping regional trends, payer priorities, and access challenges relevant to pneumonia therapeutics.
  • Enables informed decision-making through transparent segmentation, competitor profiling, and clear analysis of supply chain shifts, especially under tariff impacts.

Conclusion

The Pneumonia Therapeutics Market presents dynamic challenges and emerging opportunities shaped by innovation, regulatory change, and globalization. Strategic approaches that integrate technology, collaboration, and adaptive supply chains will underpin future leadership and sustained growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pneumonia Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Adjunctive Therapies
8.2.1. Corticosteroids
8.2.2. Nebulizers
8.3. Anti Infectives
8.3.1. Antibiotics
8.3.1.1. Aminoglycosides
8.3.1.2. Beta Lactams
8.3.1.3. Macrolides
8.3.1.4. Quinolones
8.3.1.5. Tetracyclines
8.3.2. Antifungals
8.3.3. Antivirals
8.4. Biologics
8.4.1. Immune Modulators
8.4.2. Monoclonal Antibodies
8.5. Supportive Therapies
8.5.1. Fluid Management
8.5.2. Mechanical Ventilation
8.5.3. Oxygen Therapy
9. Pneumonia Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Inhalation
9.3. Intravenous
9.4. Oral
10. Pneumonia Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Pneumonia Therapeutics Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Pneumonia Therapeutics Market, by Pathogen Type
12.1. Introduction
12.2. Atypical
12.2.1. Chlamydophila
12.2.2. Legionella
12.2.3. Mycoplasma
12.3. Bacterial
12.4. Fungal
12.5. Viral
13. Pneumonia Therapeutics Market, by Indication Type
13.1. Introduction
13.2. Community Acquired
13.3. Hospital Acquired
13.4. Ventilator Associated
14. Americas Pneumonia Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pneumonia Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pneumonia Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. GlaxoSmithKline plc
17.3.3. Merck & Co., Inc.
17.3.4. Sanofi S.A.
17.3.5. Johnson & Johnson
17.3.6. Novartis AG
17.3.7. AstraZeneca plc
17.3.8. Bayer AG
17.3.9. Teva Pharmaceutical Industries Ltd.
17.3.10. Dr. Reddy’s Laboratories Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PNEUMONIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PNEUMONIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PNEUMONIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 85. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 86. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 87. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 88. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 93. CANADA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 97. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 100. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 155. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 157. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 158. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 160. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 161. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 165. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 166. GERMANY PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 167. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 170. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 191. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 192. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 193. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 194. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 195. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 196. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 201. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 202. ITALY PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 203. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 206. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 214. SPAIN PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 253. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 254. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 257. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 261. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 262. DENMARK PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 275. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 276. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 277. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 278. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 279. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 280. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 281. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 285. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 286. QATAR PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 287. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 288. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 290. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 291. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 292. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 293. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 297. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 298. FINLAND PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 308. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 309. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 310. SWEDEN PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 320. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 321. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2030 (USD MILLION)
TABLE 322. NIGERIA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
TABLE 323. EGYPT PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 324. EGYPT PNEUMONIA THERAPEUTICS M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pneumonia Therapeutics market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • AstraZeneca plc
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.96 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pneumonia Therapeutics - Global Strategic Business Report - Product Image

Pneumonia Therapeutics - Global Strategic Business Report

  • Report
  • 100 Pages
  • Global
From
Pneumonia Therapeutics Global Market Report 2025 - Product Image

Pneumonia Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Community-acquired Pneumonia (CAP) - Pipeline Insight, 2025 - Product Image

Community-acquired Pneumonia (CAP) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Fungal Pneumonia - Pipeline Insight, 2025 - Product Image

Fungal Pneumonia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Ventilator Associated Pneumonia Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Ventilator Associated Pneumonia Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 91 Pages
  • Global
From

About the Pneumonia Drug Market

The Pneumonia Drug market is a subset of the larger Respiratory Drugs market. It includes drugs used to treat bacterial, viral, and fungal pneumonia, as well as other respiratory infections. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Commonly prescribed drugs include antibiotics, antivirals, antifungals, and corticosteroids. In addition, some drugs are used to reduce inflammation and improve breathing. The Pneumonia Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck, Sanofi, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.